Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited is set to raise approximately $4.27 million through a fully underwritten entitlement offer, allowing existing shareholders to purchase 2 new shares for every 5 held at $0.055 each. The offer aims to support the company’s development of cancer and fibrosis treatments, including its ACCENT trial for pancreatic cancer. The entitlement offer is part of Amplia’s efforts to advance its pipeline of Focal Adhesion Kinase (FAK) inhibitors.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
